Compare · AXSM vs TNYA
AXSM vs TNYA
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Tenaya Therapeutics Inc. (TNYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AXSM focuses on Biotechnology: Pharmaceutical Preparations, while TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- AXSM is the larger of the two at $8.50B, about 95.5x TNYA ($89.0M).
- Over the past year, AXSM is up 25.6% and TNYA is down 80.1% - AXSM leads by 105.7 points.
- AXSM has been more active in the news (3 items in the past 4 weeks vs 1 for TNYA).
- AXSM has more recent analyst coverage (25 ratings vs 7 for TNYA).
- Company
- Axsome Therapeutics Inc.
- Tenaya Therapeutics Inc.
- Price
- $157.09-3.00%
- $0.37-8.99%
- Market cap
- $8.50B
- $89.0M
- 1M return
- -26.73%
- -44.40%
- 1Y return
- +25.58%
- -80.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 3
- 1
- Recent ratings
- 25
- 7
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest AXSM
- Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
- Truist resumed coverage on Axsome Therapeutics with a new price target
- Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- Chief Operating Officer Jacobson Mark L. sold $2,086,500 worth of shares (10,000 units at $208.65) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $12.95 (SEC Form 4)
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
- SEC Form 10-Q filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Latest TNYA
- SEC Form PRE 14A filed by Tenaya Therapeutics Inc.
- Chief Executive Officer Ali Faraz was granted 122,000 shares, increasing direct ownership by 29% to 539,782 units (SEC Form 4)
- Chief Medical Officer Tingley Whittemore was granted 49,000 shares, increasing direct ownership by 23% to 263,073 units (SEC Form 4)
- Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
- SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.
- Chief Executive Officer Ali Faraz sold $15,778 worth of shares (22,232 units at $0.71), decreasing direct ownership by 5% to 417,782 units (SEC Form 4) to cover taxes
- Chief Medical Officer Tingley Whittemore sold $5,270 worth of shares (7,424 units at $0.71), decreasing direct ownership by 3% to 214,073 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Tenaya Therapeutics Inc.
- SEC Form S-8 filed by Tenaya Therapeutics Inc.
- SEC Form 10-Q filed by Tenaya Therapeutics Inc.